

factors using descriptive statistics. A multivariable logistic regression model was used to assess the association between cancer and prevalence of stroke survivorship. Covariates were assessed for effect modification and confounding using the maximum likelihood estimation method. **Results:** We analyzed 89,285 subjects. The prevalence of cancer and the prevalence of suffering from the effects of a stroke were 2.09% and 1.56%, respectively. Cancer was significantly associated with an increased prevalence of stroke survivorship with an odds ratio (OR) of 1.56 (95%CI: 1.24 – 1.98) after adjusting for age, sex, smoking status, education, household income, dyslipidemia, hypertension, diabetes. The association was stronger in younger age groups: the youngest age group (18 – 49 years) had the highest OR (6.49, 95%CI:2.01 – 20.94) for suffering from the effects of a stroke in association with the presence of cancer. **Conclusions:** In Canada, the presence of active cancer increases the odds of suffering from the effects of a stroke, particularly in the youngest age group.

P.074

Management, timing of anticoagulation and outcomes of patients with cerebral venous sinus thrombosis: a single centre chart review

G Mak (Hamilton)* N Chan (Hamilton), K Perera (Hamilton)
doi: 10.1017/cjn.2021.353

Background: Cerebral venous sinus thrombosis (CVST) accounts for <1% of all strokes. Our objectives were to describe the clinical features and examine the association between timing of anticoagulation therapy and outcomes in CVST patients. **Methods:** We conducted a retrospective chart review of patients admitted to Hamilton Health Sciences from 2015 – 2020 with imaging confirmed CVST. **Results:** We included 96 patients, mean age of 47.9 (SD 18.1). The most common clinical presentation was headache (43.8%). Brain trauma was the most common identified risk factor (15.6%), while 27% of individuals had no identified cause. Most patients (57.3%) received anticoagulation within 24hrs of identified CVST, while 26% had a delay (\geq 48hrs) and 16.7% were not anti-coagulated. The rationale for delaying or not starting anticoagulation included traumatic brain injury (31.8%), neurosurgical procedure (9.1%), presence of venous infarct and/or haemorrhage (27.1%) and unclear rationale (31.8%). At a median of 8 days, more patients without clear indications for delayed or no anticoagulation were disabled (defined by modified Rankin Scale, mRS, score \geq 2) or dead (mRS 6), compared to those anti-coagulated in 24hrs (87.5% versus 31.8%; RR 2.75; 95% CI 1.74 – 4.35). **Conclusions:** Unjustified delay in anticoagulation may result in poorer clinical outcomes in CVST patients.

P.075

Incidence of Stroke Associated With Antithrombotic Agent Interruption

HE Snyder (St. Catharines)* A Cao (St. Catharines) R Rana (St. Catharines) L Li (St. Catharines), F Masood (St. Catharines)
doi: 10.1017/cjn.2021.354

Background: Antithrombotic medications are used in the primary and secondary prevention of ischemic stroke. Previous studies have

identified that up to 5.2% of ischemic strokes are associated with antithrombotic interruption, leading to significant mortality and healthcare burden. Our study aims to identify the prevalence of ischemic strokes presenting to a regional stroke centre associated with antithrombotic interruption, and to understand common reasons for medication interruption. **Methods:** A retrospective chart review was performed, which included 193 patients with ischemic stroke presenting to Greater Niagara General Hospital from January 2018–December 2019. Baseline demographics were recorded and patient medical records were reviewed for evidence of antithrombotic interruptions. **Results:** Table 1. **Conclusions:** Our cohort identified a significant proportion (8.3%) of ischemic strokes with documented antithrombotic interruption. Most common reasons for interruption were non-adherence and discontinuation due to previous adverse event. The results identify possible areas for improvement within patient education and safe re-initiation of antithrombotics following adverse events.

Baseline Demographics	Total Population (n=193)	
Median Age (mean)	76 (72.8)	
Male Sex (%)	107 (55%)	
Prior Ischemic Stroke (%)	65 (34%)	
Atrial Fibrillation (%)	58 (30%)	
Smoking History (%)	66 (34%)	
Dyslipidemia (%)	102 (53%)	
Hypertension (%)	144 (75%)	
Diabetes (%)	54 (28%)	
Median Baseline NIHSS	5	
Median INR	1	
On Antithrombotic	72 (37%)	
Antiplatelet (%)	40 (21%)	56%
Anticoagulant (%)	32 (16%)	44%
Antithrombotic Interruption	16 (8.3%)	
Non-adherent	5 (2.6%)	31%
Discontinued Due to Adverse Event	7 (3.6%)	44%
Perioperative/Periprocedural Discontinuation	1 (0.5%)	6%
Other/Unclear	3 (1.6%)	19%

P.076

Hypertensive disorders in pregnancy are strongly associated with future stroke and hypertension: A systematic review and meta-analysis

AR Switzer (Calgary)* EE Smith (Calgary), A Ganesh (Calgary)
doi: 10.1017/cjn.2021.355

Background: We aimed to evaluate the association between hypertensive disorders in pregnancy (HDP) and future risk of stroke, stroke death, and hypertension. **Methods:** Systematic searches were performed in MEDLINE and EMBASE up to